Senti Biosciences Holdings (SNTI) Other Non-Current Liabilities (2022 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Other Non-Current Liabilities of $8.1 million for Q4 2025, up 60.41% year-over-year from $5.0 million in Q4 2024, and up 7.0% quarter-over-quarter from $7.6 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Other Non-Current Liabilities (2022 - 2025) Analysis & Trends
Senti Biosciences Holdings' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $8.1 million for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities rose 60.41% year-over-year to $8.1 million; the TTM figure through Dec 2025 stood at $8.1 million (up 60.41% YoY), while the FY2025 annual figure was $8.1 million, up 60.41% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $8.1 million, up from $7.6 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $8.1 million in Q4 2025, with the low at $20000.0 in Q2 2023.
- The 4-year median for Other Non-Current Liabilities is $909000.0 (2022), against an average of $3.1 million.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities tumbled 97.8% in 2023, then surged 32695.0% in 2025.
- Senti Biosciences Holdings' Other Non-Current Liabilities stood at $227000.0 in 2022, then soared by 2688.99% to $6.3 million in 2023, then dropped by 20.25% to $5.0 million in 2024, then soared by 60.41% to $8.1 million in 2025.
- Business Quant data shows SNTI's Other Non-Current Liabilities at $8.1 million in Q4 2025, $7.6 million in Q3 2025, and $7.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.10 Mn |
| Sep 30, 2025 | 7.57 Mn |
| Jun 30, 2025 | 7.57 Mn |
| Mar 31, 2025 | 6.56 Mn |
| Dec 31, 2024 | 5.05 Mn |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | 6.33 Mn |
| Sep 30, 2023 | 20,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Mar 31, 2023 | 168,000.00 |
| Dec 31, 2022 | 227,000.00 |
| Sep 30, 2022 | 909,000.00 |
| Jun 30, 2022 | 810,000.00 |